<DOC>
	<DOCNO>NCT02154360</DOCNO>
	<brief_summary>This open-label , single arm , phase I study determine safety , PK characteristic anti-inflammatory effect NK-R1 coadministered ritonavir-containing antiretroviral therapy individual well-controlled viral replication . Our hypothesis Aprepitant safe , well tolerate , anti-inflammatory property administer concomitantly protease inhibitor ritonavir .</brief_summary>
	<brief_title>Pharmacokinetic Characteristics Anti-Inflammatory Effects Aprepitant In HIV-Infected Subjects</brief_title>
	<detailed_description>This open-label , single arm , phase I study determine safety , PK characteristic anti-inflammatory effect NK-R1 coadministered ritonavir-containing antiretroviral therapy individual well-controlled viral replication . Our hypothesis Aprepitant safe , well tolerate , anti-inflammatory property administer concomitantly protease inhibitor ritonavir . The study recruit 12 participant receive either darunavir/ritonavir atazanavir/ritonavir</detailed_description>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Ritonavir</mesh_term>
	<mesh_term>Darunavir</mesh_term>
	<mesh_term>Aprepitant</mesh_term>
	<mesh_term>Fosaprepitant</mesh_term>
	<mesh_term>Anti-Inflammatory Agents</mesh_term>
	<criteria>1 . HIV1 infection , document licensed ELISA test kit confirm Western blot time prior study entry . HIV1 culture , HIV1 antigen , plasma HIV1 RNA , second antibody test method ELISA acceptable alternative confirmatory test . 2 . Antiretroviral treatment regimen include either atazanavir 300 mg daily ritonavir 100 mg daily darunavir/ritonavir combination 800/100 mg daily least 6 month prior enrollment . 3 . CD4+ cell count â‰¥ 350/mm3 least 6 month prior enrollment perform CLIAcertified laboratory . 4 . Plasma HIV1 RNA limit quantification ultrasensitive assay measure standard assay ( Roche Amplicor , UltraSensitive HIV1 Monitor assay ( Roche Molecular Systems ) , Version 3 bDNA assay ) least 6 month prior enrollment laboratory CLIAcertified ( equivalent ) assay . 5 . Laboratory value obtain within 30 day prior study entry , follow : Absolute neutrophil count ( ANC ) great equal 750/mm3 Hemoglobin great equal 10.0 g/dL Platelet count great equal 100,000/mm3 Creatinine less equal 2 x ULN ( fast ) AST ( SGOT ) , ALT ( SGPT ) , alkaline phosphatase less equal 2 x ULN Total bilirubin less equal 2.5 x ULN Albumin great equal 3 g/dL 6 . Female subject reproductive potential must negative spot urine pregnancy test result ( sensitivity least 50 mIU/mL ) perform entry , prior start initial study treatment . 7 . All subject must agree participate conception process study drug 30 day stop medication . If participate sexual activity could lead pregnancy , female study subject must use least one form contraception list receive protocolspecified medication 30 day stop medication . Condoms ( male female ) without spermicidal agent Diaphragm cervical cap spermicide IUD Female subject , reproductive potential define woman postmenopausal least 24 consecutive month , woman undergo surgical sterilization , ( e.g . hysterectomy , bilateral oophorectomy , salpingotomy ) eligible without require use contraception . Subject report history acceptable documentation sterilization , contraceptive method , menopause female 's reproductive potential . 8 . Karnofsky performance score great equal 80 within 30 day prior study entry ( Appendix I ) . 9 . Men woman great equal 18 year age . 10 . Ability willingness subject legal guardian/representative give write informed consent . 11 . Willing return followup visit day 58 . 12 . Subjects take precautionary concomitant medication must stable dos &gt; 8 week prior study entry plan change medication dos duration study . 1 . Diabetes require treatment oral hypoglycemics insulin therapy . 2 . Pregnancy within 90 day prior study entry . 3 . Use inhibitor metabolism cytochrome P450 3A4 exception ritonavir , atazanavir darunavir ( i.e . Diltiazem , Ketoconazole , Clarithromycin , Nelfinavir , Itraconazole , Nefazodone , Troleandomycin ) 4 . Use inducer metabolism cytochrome P450 3A4 ( i.e . : Rifampin , Carbamazepine , Phenytoin ) exception protease inhibitor consider trial . 5 . Breastfeeding . 6 . Use systemic corticosteroid hormonal agent within 90 day prior study entry . 7 . Use immunomodulator , HIV vaccine , investigational therapy within 90 day prior study entry . However , experimental agent short half life , determine Principal Investigator , require wash period reduce 30 day . 8 . Any vaccination within 30 day prior study entry . 9 . Use systemic cytotoxic chemotherapy within 90 day prior study entry . 10 . History allergy aprepitant formulation . 11 . Active drug alcohol use dependence , opinion investigator , would interfere adherence study requirement . 12 . History chronic active hepatitis B C infection severe hepatic dysfunction ( ChildPugh score &gt; 9 ) regardless etiology 13 . Serious illness require systemic treatment and/or hospitalization subject either complete therapy clinically stable therapy , opinion investigator , least 14 day prior study entry . 14 . Weight &lt; 40 kg 88 lb . within 90 day prior study entry . 15 . History severe psychiatric comorbidities , depression , schizophrenia , mania , psychosis</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2016</verification_date>
	<keyword>HIV infection</keyword>
	<keyword>NK-1R antagonist</keyword>
	<keyword>aprepitant</keyword>
	<keyword>ritonavir boost</keyword>
</DOC>